Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ANZUP 2023 | PREPARE: treating retrograde ejaculation in testicular cancer with pseudoephedrine

Ciara Conduit, FRACP, MBBS, PGCert MEd, Peter MacCallum Cancer Centre, Melbourne, Australia, provides an overview of the Phase II PREPARE trial, which assessed pseudoephedrine for retrograde ejaculation in patients with testicular cancer who have undergone retroperitoneal lymph node dissection (RPLND). The trial is split into two parts, where the first part (ACTRN12622000537752) consists of a questionnaire regarding sexual function and fertility, and the second part (ACTRN12622000542796) consists of patients receiving pseudoephedrine. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.